Benitec Biopharma (BNTC) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rocket Pharmaceuticals (RCKT) has outperformed Benitec Biopharma (BNTC) over the past year, losing 22.4% versus a loss of 37.9%. Over five years, BNTC leads with a -85.7% price change compared with -90.6% for RCKT. Benitec Biopharma is the larger company by market cap ($305.2 million vs $288.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTC | RCKT |
|---|---|---|
| Share price | $8.75 | $2.63 |
| Market cap | $305.22M | $288.71M |
| 1-day change | -2.67% | +3.75% |
| YTD return | -35.04% | -25.07% |
| 1-year return | -37.94% | -22.42% |
| 5-year return | -85.66% | -90.58% |
| EPS (TTM) | $-0.98 | $-0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.76 | $5.45 |
| 52-week low | $8.52 | $2.42 |
| Distance from 52-week high | -47.79% | -51.74% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +178.06% | +223.19% |
| Average volume | 152.08K | 1.66M |
| Shares outstanding | 34.88M | 109.77M |
| Employees | 24 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCKT has outperformed BNTC by 15.5 percentage points over the past year.
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
BNTC vs RCKT FAQ
Which is bigger, Benitec Biopharma or Rocket Pharmaceuticals?
Benitec Biopharma (BNTC) is larger, with a market capitalization of $305.22M compared with $288.71M for Rocket Pharmaceuticals (RCKT).
Which stock has performed better over the past year, BNTC or RCKT?
RCKT returned -22.42% over the past 12 months, compared with -37.94% for BNTC (price return, excluding dividends). Past performance does not predict future results.
Are Benitec Biopharma and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.